



Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/691,094		
		Filing Date	October 22, 2003		
		First Named Inventor	John H. GRIFFIN		
		Art Unit	1626		
		Examiner Name	Janet L. Coppins		
Sheet	1	of	1	Attorney Docket Number	P-144-US2

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)					
JLC	A1	US-	2004/0045044 A1	03-04-2004	Briesewitz et al.		
JLC	A2	US-	11/008,746	Filed 12-09-2004	Briesewitz		
FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
JLC	C17	AIELLO et al., "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", Proc. Natl. Acad. Sci USA, Vol. 92, pp 10457-10461, November 1995					
JLC	C18	DREVS et al., "Effects of PTK787/ZK 222584, a Specific Inhibitor of Fascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model", Cancer Research 60, pp 4819-4824 (September 1, 2000)					
JLC	C19	MENDEL et al., "In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship", Clinical Cancer Research, Vol. 9, pp 327-337 (January 2003)					
JLC	C20	WOOD, "Inhibition of Vascular Endothelial Growth Factor (VEGF) as a Novel Approach for Cancer Therapy", Medicina (Buenos Aires) 60 (Supl. II), pp 41-47 (2000)					
JLC	C21	ZWICK et al., "Receptor tyrosine kinase signalling as a target for cancer intervention strategies", Endocrine-Related Cancer, Vol. 8, pp 161-173 (2001)					

Examiner Signature	<i>Janet L. Coppins</i>	Date Considered	9/1/05
-----------------------	-------------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.